PUSHING THE BOUNDARIES IN ABD | Webinar 2
Strategic Use of Advanced Technologies and Multiple Host Species to Rapidly Generate Cost-Effective Antibody Candidates
Overview
Genovac leverages cutting-edge AI-driven in silico humanization, multi-host species screening, and the Beaconยฎ optofluidic system to accelerate antibody discovery. By integrating diverse immune repertoires and advanced discovery platforms, researchers can enhance lead optimization, increase hit diversity, and improve success rates against difficult targets like RAGE.
This webinar will highlight how Genovac's innovative approach streamlines antibody candidate generation, reduces downstream engineering needs, and improves developability profiles. Discover how wild-type host systems, machine learning in lead optimization, and the Beaconยฎ system work together to drive faster, more efficient therapeutic lead development.
Speakers
Iwona Budnicki, Ph.D.
Manager, Cellular Immunology, Genovac
Iwona Budnicki leads the single B-cell antibody discovery technology group at Genovac where she is responsible for the development of processes on and around Bruker Cellular Analysisโ Beacon platform for the discovery of antibodies against challenging targets. Iwona earned her PhD from the Friedrich-Schiller-University Jena, Germany and has ten years of experience in immunobiology. Her work in the field of T cells and infectious diseases has resulted in several publications in peer-reviewed journals.
Donovan McGinley-Colman
Senior Scientist, Genovac
Donovan McGinley-Colman is a Senior Scientist at Genovac Antibody Discovery. He graduated from North Dakota State University with a Bachelor of Science in Biochemistry. Out of college, he worked for American Preclinical Services supporting PK and E&L studies. Donovan joined Genovac in 2021, where he currently leads implementation and project management pertaining to downstream purification, testing, and characterization through SPR and BLI techniques.
Danielle Borys
Senior Product Applications Scientist, Bruker Cellular Analysis
Danielle Borys is a Senior Product Applications Scientist at Bruker Cellular Analysis. She joined IsoPlexis in 2019 as a senior research associate, and transitioned through scientist roles in research, product development, and client collaborations. Following Brukerโs acquisition, Danielle continues to support proteomic products on the IsoSparkยฎ system and antibody discovery products on the Beaconยฎ optofluidic system.
In Partnership With
Live Webcast Details
Key Takeaways
- Enhanced Antibody Discovery with Multiple Host Species: Learn how leveraging diverse immune repertoires across multiple species improves success rates against difficult targets like RAGE.
- AI-Powered Humanization & Lead Optimization: Discover how in silico humanization and machine learning accelerate lead identification and developability, reducing downstream engineering efforts.
- Cutting-Edge Technologies for Faster Antibody Development: Explore how Genovac integrates the Beaconยฎ optofluidic system, wild-type host systems, and advanced discovery platforms to streamline and accelerate antibody discovery and characterization.